Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

Grazia D'Onofrio, Francesco Panza, Vincenza Frisardi, Vincenzo Solfrizzi, Bruno P. Imbimbo, Giulia Paroni, Leandro Cascavilla, Davide Seripa, Alberto Pilotto

Research output: Contribution to journalArticle

Abstract

Introduction: In an attempt of altering the natural history of Alzheimer's disease (AD), several compounds have been developed with the aim of inhibiting γ-secretase, the enzymatic complex generating β-amyloid (Aβ) peptides (Aβ1 40 and Aβ1 42), from amyloid precursor protein (APP). APP is believed to be involved in the pathophysiological cascade of AD. Areas covered: This article briefly reviews the profile of γ-secretase inhibitors that have reached the clinic. The paper reviews studies from the primary English literature on γ-secretase inhibitors published before November 2011, searching through the PubMed database of NCBI by author and the following keywords: drugs targeting β-amyloid, γ-secretase inhibitors, dementia syndromes and Alzheimer's disease. Expert opinion: Studies in both transgenic and non-transgenic animal models of AD have indicated that γ-secretase inhibitors, administered by the oral route, are able to lower brain Aβ concentrations. However, scanty data are available on the effects of these compounds on brain Aβ deposition after prolonged administration. γ-Secretase inhibitors may cause significant toxicity in experimental animals and in humans believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions. Unfortunately, two large Phase III clinical trials of semagacestat in mild-to-moderate AD patients were prematurely interrupted because of the observation of a detrimental cognitive and functional effects of the drug, possibly due to its lack of selectivity on APP processing. New APP-selective γ-secretase inhibitors are being developed with the hope of overcoming the previous setbacks.

Original languageEnglish
Pages (from-to)19-37
Number of pages19
JournalExpert Opinion on Drug Discovery
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Amyloid Precursor Protein Secretases
Alzheimer Disease
Amyloid beta-Protein Precursor
Amyloid
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Therapeutics
Literature
Phase III Clinical Trials
Brain
Expert Testimony
Drug Delivery Systems
PubMed
Dementia
Animal Models
Observation
Databases
Peptides
Pharmaceutical Preparations

Keywords

  • β-amyloid
  • γ-Secretase inhibitors
  • Alzheimer's disease
  • Notch processing

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. / D'Onofrio, Grazia; Panza, Francesco; Frisardi, Vincenza; Solfrizzi, Vincenzo; Imbimbo, Bruno P.; Paroni, Giulia; Cascavilla, Leandro; Seripa, Davide; Pilotto, Alberto.

In: Expert Opinion on Drug Discovery, Vol. 7, No. 1, 01.2012, p. 19-37.

Research output: Contribution to journalArticle

D'Onofrio, Grazia ; Panza, Francesco ; Frisardi, Vincenza ; Solfrizzi, Vincenzo ; Imbimbo, Bruno P. ; Paroni, Giulia ; Cascavilla, Leandro ; Seripa, Davide ; Pilotto, Alberto. / Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. In: Expert Opinion on Drug Discovery. 2012 ; Vol. 7, No. 1. pp. 19-37.
@article{d59e316f9be7453b8186eb79b47543bc,
title = "Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease",
abstract = "Introduction: In an attempt of altering the natural history of Alzheimer's disease (AD), several compounds have been developed with the aim of inhibiting γ-secretase, the enzymatic complex generating β-amyloid (Aβ) peptides (Aβ1 40 and Aβ1 42), from amyloid precursor protein (APP). APP is believed to be involved in the pathophysiological cascade of AD. Areas covered: This article briefly reviews the profile of γ-secretase inhibitors that have reached the clinic. The paper reviews studies from the primary English literature on γ-secretase inhibitors published before November 2011, searching through the PubMed database of NCBI by author and the following keywords: drugs targeting β-amyloid, γ-secretase inhibitors, dementia syndromes and Alzheimer's disease. Expert opinion: Studies in both transgenic and non-transgenic animal models of AD have indicated that γ-secretase inhibitors, administered by the oral route, are able to lower brain Aβ concentrations. However, scanty data are available on the effects of these compounds on brain Aβ deposition after prolonged administration. γ-Secretase inhibitors may cause significant toxicity in experimental animals and in humans believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions. Unfortunately, two large Phase III clinical trials of semagacestat in mild-to-moderate AD patients were prematurely interrupted because of the observation of a detrimental cognitive and functional effects of the drug, possibly due to its lack of selectivity on APP processing. New APP-selective γ-secretase inhibitors are being developed with the hope of overcoming the previous setbacks.",
keywords = "β-amyloid, γ-Secretase inhibitors, Alzheimer's disease, Notch processing",
author = "Grazia D'Onofrio and Francesco Panza and Vincenza Frisardi and Vincenzo Solfrizzi and Imbimbo, {Bruno P.} and Giulia Paroni and Leandro Cascavilla and Davide Seripa and Alberto Pilotto",
year = "2012",
month = "1",
doi = "10.1517/17460441.2012.645534",
language = "English",
volume = "7",
pages = "19--37",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

AU - D'Onofrio, Grazia

AU - Panza, Francesco

AU - Frisardi, Vincenza

AU - Solfrizzi, Vincenzo

AU - Imbimbo, Bruno P.

AU - Paroni, Giulia

AU - Cascavilla, Leandro

AU - Seripa, Davide

AU - Pilotto, Alberto

PY - 2012/1

Y1 - 2012/1

N2 - Introduction: In an attempt of altering the natural history of Alzheimer's disease (AD), several compounds have been developed with the aim of inhibiting γ-secretase, the enzymatic complex generating β-amyloid (Aβ) peptides (Aβ1 40 and Aβ1 42), from amyloid precursor protein (APP). APP is believed to be involved in the pathophysiological cascade of AD. Areas covered: This article briefly reviews the profile of γ-secretase inhibitors that have reached the clinic. The paper reviews studies from the primary English literature on γ-secretase inhibitors published before November 2011, searching through the PubMed database of NCBI by author and the following keywords: drugs targeting β-amyloid, γ-secretase inhibitors, dementia syndromes and Alzheimer's disease. Expert opinion: Studies in both transgenic and non-transgenic animal models of AD have indicated that γ-secretase inhibitors, administered by the oral route, are able to lower brain Aβ concentrations. However, scanty data are available on the effects of these compounds on brain Aβ deposition after prolonged administration. γ-Secretase inhibitors may cause significant toxicity in experimental animals and in humans believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions. Unfortunately, two large Phase III clinical trials of semagacestat in mild-to-moderate AD patients were prematurely interrupted because of the observation of a detrimental cognitive and functional effects of the drug, possibly due to its lack of selectivity on APP processing. New APP-selective γ-secretase inhibitors are being developed with the hope of overcoming the previous setbacks.

AB - Introduction: In an attempt of altering the natural history of Alzheimer's disease (AD), several compounds have been developed with the aim of inhibiting γ-secretase, the enzymatic complex generating β-amyloid (Aβ) peptides (Aβ1 40 and Aβ1 42), from amyloid precursor protein (APP). APP is believed to be involved in the pathophysiological cascade of AD. Areas covered: This article briefly reviews the profile of γ-secretase inhibitors that have reached the clinic. The paper reviews studies from the primary English literature on γ-secretase inhibitors published before November 2011, searching through the PubMed database of NCBI by author and the following keywords: drugs targeting β-amyloid, γ-secretase inhibitors, dementia syndromes and Alzheimer's disease. Expert opinion: Studies in both transgenic and non-transgenic animal models of AD have indicated that γ-secretase inhibitors, administered by the oral route, are able to lower brain Aβ concentrations. However, scanty data are available on the effects of these compounds on brain Aβ deposition after prolonged administration. γ-Secretase inhibitors may cause significant toxicity in experimental animals and in humans believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions. Unfortunately, two large Phase III clinical trials of semagacestat in mild-to-moderate AD patients were prematurely interrupted because of the observation of a detrimental cognitive and functional effects of the drug, possibly due to its lack of selectivity on APP processing. New APP-selective γ-secretase inhibitors are being developed with the hope of overcoming the previous setbacks.

KW - β-amyloid

KW - γ-Secretase inhibitors

KW - Alzheimer's disease

KW - Notch processing

UR - http://www.scopus.com/inward/record.url?scp=84855414394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855414394&partnerID=8YFLogxK

U2 - 10.1517/17460441.2012.645534

DO - 10.1517/17460441.2012.645534

M3 - Article

C2 - 22468891

AN - SCOPUS:84855414394

VL - 7

SP - 19

EP - 37

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 1

ER -